Literature DB >> 28938930

Re: Good: Bevacizumab for retinopathy of prematurity: treatment when pathology is embedded in a normally developing vascular system (Ophthalmology. 2016;123:1843-1844).

Michael P Blair1, Michael J Shapiro2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28938930     DOI： 10.1016/j.ophtha.2017.05.007

Source DB:  PubMed          Journal:  Ophthalmology        ISSN： 0161-6420            Impact factor:   12.079


× No keyword cloud information.
  4 in total

1.  Reply to comment on: "Advantages of bevacizumab for aggressive posterior retinopathy of prematurity".

Authors:  Sidney A Schechet; Sarah Hilkert Rodriguez; Michael J Shapiro; Michael P Blair
Journal:  Taiwan J Ophthalmol       Date:  2019 Apr-Jun

2.  Postnatal Growth Trajectories and Neurodevelopmental Outcomes Following Bevacizumab Treatment for Retinopathy of Prematurity.

Authors:  David L Zhang; Hawke H Yoon; Raye-Ann O deRegnier; Jennifer Arzu; Safa Rahmani
Journal:  Clin Ophthalmol       Date:  2022-08-20

Review 3.  Complications of retinopathy of prematurity treatment.

Authors:  Joshua M Barnett; G Baker Hubbard
Journal:  Curr Opin Ophthalmol       Date:  2021-09-01       Impact factor: 4.299

4.  Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.

Authors:  Gerard P Barry; Yinxi Yu; Gui-Shuang Ying; Lauren A Tomlinson; Juliann Lajoie; Marilyn Fisher; Gil Binenbaum
Journal:  Ophthalmology       Date:  2020-12-31       Impact factor: 14.277
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.